invest summari reiter overweight rate rais
pt share increas pt driven multipl
expans think deserv respect earn growth driven
innov medicin recent pipelin advanc return capit
sharehold industri averag still underappreci
 valuat use blend ev/ebitda multipl increas
peer averag dcf analysi ev/ebit exit multipl
increas peer averag ev/ebit arriv
new pt
 chang mind dilig exist opportun
bullish peak sale potenti ibranc upsid
expect could driven ou sale well use drug
earlier stage set pleas see recent note detail also within
past year xeljanz receiv approv two addit indic psoriat
arthriti ulcer coliti uc expect combin new
indic add sale xeljanz context report
sale xeljanz sale entir compani
xeljanz note deeper dive upsid opportun product
final receiv fda approv expand indic xtandi
includ men non-metastat castrate-resist prostat cancer nmcrpc
make xtandi first oral medic approv nmcrpc
metastat previous said non-metastat
prostat cancer market size metastat market combin
prospect longer treatment durat
 also increasingli posit two pipelin
opportun tafadmidi tanezumab note
thought
disclosur section may found page
use blend ev/ebitda multipl increas peer averag
dcf analysi ev/ebit exit multipl increas peer
averag ev/ebit arriv pt
sever potenti risk invest thesi price target
product repres signific portion sale could face gener
competit current portfolio product may face competit cannib
pipelin introduct new competit could diminish price
power exist drug record direct product and/or allianc revenu
billion nine biopharmaceut product prevnar lyrica
ibranc eliqui enbrel lipitor xeljanz viagra sutent account total
revenu product pfizer major product subject
problem loss patent protect applic chang prescript growth rate
affect doctor patient confid pressur exist competit product chang
label access pressur new more-effect treatment introduc
advers impact revenu could signific
pipelin delay failur and/or higher-than-forecast competit gener
may continu face access challeng biosimilar product market
biosimilar product may receiv access pariti innov product remain
disadvantag posit exampl inflectra/remsima experienc access challeng
risk relat strateg acquisit success recent acquisit
hospira anacor mediv astrazeneca small molecul anti-infect busi
depend larg part compani abil realiz anticip benefit combin
busi exist segment exampl may fail achiev
anticip cost save acquisit hospira cost save within
expect time frame accret impact anticip acquisit hospira
anacor mediv may realiz may delay also may fail gener
revenu growth acquir busi expect time enter
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
exhibit catalyst event calendar
exhibit catalyst event calendar continu
fitzgerald million except per share sale si tax rate adjust weighted-averag share dilut cantor fitzgerald research compani updat revenu guidanc updat sole reflect recent unfavor chang foreign exchang rate relat usdfrom mid-april mid-juli primarili weaken euro chines yuan japanes guidanc adjust expens updat primarili reflect higher anticip spend previous project larg relat late-stag develop guidanc adjust incom /deduct updat primarili reflect unreal net gain equiti secur one-tim mileston payment certain collabor out-licens arrang gain sale certain compound/product right current expect tax rate guidanc sustain beyond guidanc adjust dilut ep reflect share repurchas total alreadi complet dilut relat share-bas employe compens program expect off-set half reduct share associ share juli remain share repurchas author guidanc reflect anticip neg revenu impact due recent expect gener biosimilar competit certain product recent lost anticip soon lose patent protect assum gener competit lyrica june conting upon six-month patent-term extens grant fda pediatr exclus current guidanc reflect full year contribut consum healthcar continu expect decis regard strateg altern consum healthcar made guidanc reflect anticip favor impact approxim revenu adjust dilut ep result favor chang foreign exchang rate rel usd compar foreign exchang rate expect broaden biosimilar portfolio potenti bring five biosimilar market next year compani biosimilar either registr enter registr next expect steril inject busi see yoy improv see potenti approv blockbust potenti includ xeljanz eliqui make half novel oral equival prescript widen market share lead thequart primari current realiz list price rest goe subsid pbm insur compani premium healthi patient compani believ remov rebat trap advantag xeljanz biosimilar program believ limitingpric increas futur low singl digit affect abil reach middle-to-high singl digit top-line growth exhibit incom statement analysi
million except per share amount compound-annual-growth-rate year end decemb incom attribut share dilut changetot share dilut cantor fitzgerald research compani report includ royalty-rel incom net gain asset dispos incom collabor out-licens arrang sale compound/product right net unreal gain equiti secur net period benefit costs/credit servic cost certain legal matter net certain asset impair loss sale net asset busi legal entiti align cost net non- adjust incom /deduct net exclud purchas account adjust certain signific purchas account impact result busi combin net asset acquisit primarili associ wyeth hospira anacor mediv acquisition-rel cost transact integr restructur addit depreci cost associ busi combin discontinu oper result oper includ discontinu oper well relat gain loss dispos oper certain signific item substant and/or unusu item evalu individu basi exclud purchas account adjust certain signific purchas account impact result busi combin net asset acquisit primarili associ wyeth hospira anacor mediv acquisition-rel cost transact integr restructur addit depreci cost associ busi combin discontinu oper result oper includ discontinu oper well relat gain loss dispos oper certain signific item substant and/or unusu item evalu individu basi compar total revenu unfavor impact result one less sell day intern market remain share-purchas author exclud purchas account adjust acquisition-rel cost discontinu oper certain signific item exclud purchas account adjust acquisition-rel cost discontinu oper certain signific item exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb innov ih intern revenu us essenti eh legaci establish product inject pharmaceut infus -- -- -- net revenu us innov ih intern revenu essenti eh legaci establish product steril inject pharmaceut infus -- -- -- net revenu changeu innov ih intern revenu us essenti eh legaci establish product inject pharmaceut infus revenu us innov ih intern revenu essenti eh legaci establish product inject pharmaceut infus revenu cantor fitzgerald research compani report exhibit annual sale analysi
innov ih intern revenu us essenti eh legaci establish product inject pharmaceut infus revenu us innov ih intern revenu essenti eh legaci establish product inject pharmaceut infus revenu avelumab cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million decemb fiscal oper activitynet incom alloc non-controlling depreci chang oper asset net oper invest activ purchas purchas short-term proce redemptions/sal short-term purchas long-term proce redemptions/sal long-term acquisit busi net cash acquisit intang invest activ net invest financ activitiesproce from/ payment short-term princip payment short-term proce issuanc long-term princip payment long-term purchas common dividend proce exercis stock financ activ net financ effect exchange-r chang cash cash net increas decreas cash cash equival equival sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million decemb fiscal assetscash cash short-term trade account receiv current tax current total current long-term ppe less accumul identifi intang asset less accumul non-current defer tax asset non-current tax non-current total liabil sharehold equitycurr liabilitiesshort-term borrow incl current portion lt trade account dividend incom tax accru compens relat current total current long term pension benefit oblig postretir benefit oblig non-current defer tax tax non-current total sharehold equitypref common addit paid treasuri retain accumul comprehens incom total sharehold equiti attribut non-controlling total total liabili sourc cantor fitzgerald research compani report octob
pfizer inc engag discoveri develop manufactur healthcar product special medicin vaccin
consum healthcar oper pfizer innov health ih pfizer essenti health eh segment ih
segment focus develop commerci medicin vaccin intern medicin oncolog inflamm
immunolog rate diseas consum healthcar eh segment involv develop suppli brand gener gener
steril inject product biosimilar select brand product includ anti-infect
